Predictive impact of the inflammation-based indices in uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion

被引：10

作者：

Ludwig, Johannes M. ^{[1
]}

Haubold, Johannes ^{[1
]}

Bauer, Sebastian ^{[2
]}

Richly, Heike ^{[2
]}

Siveke, Jens T. ^{[3
,4
,5
]}

Wimmer, Julia ^{[1
]}

Umutlu, Lale ^{[1
]}

Schaarschmidt, Benedikt M. ^{[1
]}

Theysohn, Jens M. ^{[1
]}

机构：

[1] Univ Duisburg Essen, Univ Hosp Essen, Dept Diagnost & Intervent Radiol & Neuroradiol, Hufelandstr 55, D-45147 Essen, Germany

[2] Univ Duisburg Essen, Sarcoma Ctr, West German Canc Ctr, Dept Med Oncol, Essen, Germany

[3] Univ Hosp Essen, West German Canc Ctr, Inst Dev Canc Therapeut, Essen, Germany

[4] DKFZ, Div Solid Tumor Translat Oncol, German Canc Consortium DKTK, Partner Site Essen, Heidelberg, Germany

[5] DKFZ, German Canc Res Ctr, Heidelberg, Germany

来源：

RADIOLOGY AND ONCOLOGY | 2021年 / 55卷 / 03期

关键词：

uveal melanoma; liver metastases; transarterial hepatic chemoperfusion; melphalan; inflammatory markers; CANCER; SURVIVAL; PROGNOSIS; DISEASE; CELLS;

D O I：

10.2478/raon-2021-0027

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background. The aim of the study was to evaluate pretreatment inflammatory markers as prognostic factors in patients with unresectable uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion. Patients and methods. 54 patients (44% male, median age: 61 years) were retrospectively assessed. A median of 3 (range: 1-11) treatment sessions were performed with melphalan (92%) or fotemustin (8%). Inflammatory indices were calculated as follows: neutrophils/nl to lymphocytes/nl ratio (NLR), systemic immune-inflammation index ([platelets/nl x neutrophils/nl]/[lymphocytes/nl]; SII), and platelets/nl to lymphocytes/nl ratio (PLR). The cut-off for dichotomization purposes was set at the median (inflammatory indices, hepatic tumor burden) or the upper level of normal. Kaplan Meier analysis was performed for median overall survival (OS) in months, and Cox proportional hazard model for uni(UVA) and multivariate (MVA) hazard ratio (HR, 95%CI) analyses were performed. Results. Median OS of the study cohort was 7.7 (6.3-10.9) months. In UVA OS was prolonged for low C reactive protein (CRP) (13.5 vs. 5.2; p = 0.0005), low SII (10.8 vs. 5.6; p = 0.0005), low NLR (11.1 vs. 6.3; p = 0.0045), low aspartate aminotransferase (AST) (11.5 vs. 5.6; p = 0.015), alanine aminotransferases (ALT) (11.5 vs. 5.6; p = 0.01), and tumor burden <_ 50% (8.2 vs. 4.8; p = 0.007). MVA confirmed low CRP (HR: 0.29, 0.11-0.7; p = 0.005), low SII (HR: 0.19, 0.11-0.7; p = 0.008), and low ALT (HR: 0.13, 0.02-0.63; p = 0.011) as independent predictors for prolonged OS. Patients with <_ 1, 2, 3 elevated significant MVA-factors survived a median of 14.9, 7.7, and 3.9 months, respectively (p = 0.0001). Conclusions. Pretreatment inflammatory markers (CRP, SII) and AST were independent prognostic survival markers in patients with uveal melanoma liver metastases treated with transarterial hepatic chemoperfusion. A combination of factors may help to identify patients potentially benefitting from treatment.

引用

页码：347 / 353

页数：7

共 31 条

[1] Inflammation in uveal melanoma [J].